| 5.54 0 (0%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.57 | 1-year : | 7.68 |
| Resists | First : | 5.63 | Second : | 6.57 |
| Pivot price | 5.51  |
|||
| Supports | First : | 4.82 | Second : | 4.32 |
| MAs | MA(5) : | 5.54  |
MA(20) : | 5.53 |
| MA(100) : | 4.65 |
MA(250) : | 4 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 93.1 | D(3) : | 93.2 |
| RSI | RSI(14): 52.4 | |||
| 52-week | High : | 5.65 | Low : | 2.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALIM ] has closed below upper band by 43.6%. Bollinger Bands are 57.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.55 - 5.58 | 5.58 - 5.6 |
| Low: | 5.47 - 5.5 | 5.5 - 5.53 |
| Close: | 5.5 - 5.54 | 5.54 - 5.58 |
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Mon, 16 Sep 2024
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences - GlobeNewswire
Mon, 16 Sep 2024
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences - StockTitan
Mon, 16 Sep 2024
ANI Pharmaceuticals finalizes acquisition of Alimera Sciences - Investing.com
Mon, 16 Sep 2024
Alimera Sciences, Inc. (NASDAQ:ALIM) Sees Large Drop in Short Interest - MarketBeat
Thu, 12 Sep 2024
Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock? - Yahoo Finance
Thu, 12 Sep 2024
Alimera Sciences, Inc. (NASDAQ:ALIM): When Will It Breakeven? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 54 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 86.5 (%) |
| Shares Short | 578 (K) |
| Shares Short P.Month | 646 (K) |
| EPS | 1.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.74 |
| Profit Margin | -14.8 % |
| Operating Margin | 7.8 % |
| Return on Assets (ttm) | 0.9 % |
| Return on Equity (ttm) | -34.6 % |
| Qtrly Rev. Growth | 54 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.83 |
| EBITDA (p.s.) | 0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | 5.27 |
| PEG Ratio | 0 |
| Price to Book value | 7.48 |
| Price to Sales | 3.02 |
| Price to Cash Flow | -53.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|